Mullusiem (Atorvastatin)

Atorvastatin, the active ingredient in Mullusiem, is a HMG‑CoA reductase inhibitor presented as an oral dosage form for oral use. It lowers elevated cholesterol and triglyceride levels and is used to reduce cardiovascular risk in adults with hypercholesterolemia or mixed dyslipidemia.

GNH USA supplies Mullusiem as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Atorvastatin acts on lipid metabolism disorders and is indicated for several cardiovascular‑related conditions. - Hypercholesterolemia: reduces LDL‑cholesterol to lower risk of atherosclerotic disease. - Mixed dyslipidemia: improves overall lipid profile by lowering triglycerides and raising HDL‑cholesterol. - Primary prevention of cardiovascular disease: decreases incidence of heart attack and stroke in at‑risk patients. - Secondary prevention of cardiovascular disease: limits recurrent events in patients with established coronary artery disease.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate discomfort. - Myalgia: muscle aches without weakness. - Abdominal pain: discomfort in the stomach area. - Nausea: feeling of queasiness. - Constipation: infrequent bowel movements. - Elevated liver enzymes: mild increase in hepatic transaminases.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown that can lead to renal failure. - Acute liver injury: marked elevation of liver function tests or hepatitis. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Myopathy: muscle weakness with elevated creatine kinase levels.

Before initiating therapy, consider patient‑specific factors and monitoring requirements. - Hepatic impairment: assess liver function before starting and periodically thereafter. - Renal impairment: monitor renal function and adjust therapy as needed. - Pregnancy: avoid use unless potential benefit justifies risk to the fetus. - Concomitant medications: review for possible drug‑drug interactions that may increase toxicity. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Atorvastatin may interact with other medicines, requiring avoidance or careful monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): may markedly increase atorvastatin exposure. - Gemfibrozil: combined use raises risk of myopathy and rhabdomyolysis. - Protease inhibitors (e.g., ritonavir): can substantially elevate plasma concentrations.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may reduce absorption of atorvastatin. - Warfarin: concurrent use can enhance anticoagulant effect, requiring INR monitoring. - Niacin: combined therapy may increase risk of hepatic dysfunction.